Arcturus Therapeutics Holdings Inc. (ARCT) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ARCT Revenue Growth
Revenue Breakdown (FY 2025)
ARCT's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
ARCT Revenue Analysis (2014–2025)
As of May 8, 2026, Arcturus Therapeutics Holdings Inc. (ARCT) generated trailing twelve-month (TTM) revenue of $74.1 million, reflecting significant decline in growth of -85.3% year-over-year. The most recent quarter (Q4 2025) recorded $3.1 million in revenue, down 82.0% sequentially.
Looking at the longer-term picture, ARCT's 5-year compound annual growth rate (CAGR) stands at +47.8%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $205.8 million in 2022.
Revenue diversification analysis shows ARCT's business is primarily driven by Collaboration Revenue (82%), and Grant (18%). With over half of revenue concentrated in Collaboration Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including MRNA (-29.1% YoY), BNTX (+4.0% YoY), and NTLA (+16.9% YoY), ARCT has underperformed the peer group in terms of revenue growth. Compare ARCT vs MRNA →
ARCT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ARCTCurrent | $74M | -85.3% | +47.8% | -111.5% | |
 MRNA | $1.9B | -29.1% | +19.3% | -158.1% | |
 BNTX | $2.8B | +4.0% | +41.7% | -22.6% | |
 NTLA | $68M | +16.9% | +3.1% | -651.7% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% |
ARCT Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $67.2M | -51.4% | $64.2M | 95.5% | $-74,955,000 | -111.5% |
| 2024 | $138.4M | -12.3% | $138.4M | 100.0% | $-95,669,000 | -69.1% |
| 2023 | $157.7M | -23.3% | $157.7M | 100.0% | $-78,205,000 | -49.6% |
| 2022 | $205.8M | +1564.8% | $205.8M | 100.0% | $12.2M | 5.9% |
| 2021 | $12.4M | +29.6% | $12.4M | 100.0% | $-202,852,000 | -1641.3% |
| 2020 | $9.5M | -54.1% | $-46,407,000 | -486.5% | $-71,524,000 | -749.8% |
| 2019 | $20.8M | +32.0% | $20.8M | 100.0% | $-25,513,000 | -122.7% |
| 2018 | $15.8M | +21.2% | $-1,229,000 | -7.8% | $-21,811,000 | -138.5% |
| 2017 | $13.0M | -36.2% | $12.6M | 96.8% | $-10,492,000 | -80.7% |
| 2016 | $20.4M | +232.1% | $20.1M | 98.6% | $-25,167,000 | -123.5% |
See ARCT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARCT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ARCT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonARCT — Frequently Asked Questions
Quick answers to the most common questions about buying ARCT stock.
Is ARCT's revenue growth accelerating or slowing?
ARCT revenue declined -85.3% year-over-year, contrasting with the 5-year CAGR of +47.8%. TTM revenue fell to $74M. This reverses the prior growth trend.
What is ARCT's long-term revenue growth rate?
Arcturus Therapeutics Holdings Inc.'s 5-year revenue CAGR of +47.8% reflects the variable expansion pattern. Current YoY growth of -85.3% is below this long-term average.
How is ARCT's revenue distributed by segment?
ARCT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.